Rosuvastatin (Crestor, AstraZeneca), a cholesterol-lowering agent, is currently the most-prescribed drug among the 100 most-prescribed and best-selling drugs in the United States. In the past 12 months, new prescriptions and refills for rosuvastatin have been estimated to amount to 23.7 million.
Post-hoc analysis found that, despite continued titration with insulin glargine, more diabetes patients achieved sustained glycemic control with exenatide once-weekly, according to data presented at the Annual Meeting of the European Association for the Study of Diabetes (EASD) in Vienna, Austria.
American Diabetes Association Scientific Sessions in San Francisco, showed that investigational, non-insulin, once-weekly dulaglutide 1.5 mg provided significant blood glucose control for patients with type 2 diabetes.
LY2963016 insulin glargine has a similar safety and efficacy profile to currently marketed insulin glargine, according to data recently presented the American Diabetes Association (ADA) Scientific Sessions in San Francisco.